Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upcoming October Conferences
BURLINGTON, MA — October 8, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that management will participate in two upcoming industry conferences to highlight C-1101, the company’s novel, platelet-derived multi-protein biologic therapeutic designed to treat lumbosacral radiculopathy (LSR), or chronic sciatica. On October 15, 2026, Consano Bio will present at Align Summit, MassBio’s annual partnering conference, in Boston, MA, and on October 28, 2026, management will participate in a panel discussion at the BioFuture conference in New York, NY. READ MORE
Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)
BURLINGTON, MA — October 5, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that it has completed an oversubscribed financing, raising more than its $15 million target to support the clinical development of C-1101, the company’s lead investigational therapy. The financing was subscribed by a syndicate of accredited private investors, and including this transaction, Consano Bio has now raised more than $45 million in the three years since inception. READ MORE
Consano Bio Announces Peer-Reviewed Publication Supporting the Therapeutic Potential of C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
BURLINGTON, MA — September 10, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics for serious, painful orthopedic conditions, today announced the publication of nonclinical research in Frontiers in Bioengineering and Biotechnology evaluating the biological activity of C‑1101, the Company’s lead candidate, in clinical development for chronic painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. READ MORE
Consano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
BURLINGTON, MA — August 18, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to C-1101, the Company’s lead investigational, platelet-derived biologic for the treatment of chronic, painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. Presently, there are no FDA-approved pharmaceutical therapies indicated to treat LSR. READ MORE
Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States
BURLINGTON, MA — July 20, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for C-1101, its lead investigational therapy for chronic painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. READ MORE
Consano Bio Highlights Scientific Advisory Board for C-1101, a Potential First-in-Class, Non-Opioid Therapy in Development for Chronic Sciatica
BURLINGTON, MA — June 29, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101, the company’s potential first-in-class, disease-modifying, non-opioid therapy for painful chronic lumbosacral radiculopathy (LSR), or chronic sciatica. READ MORE
Consano Bio to Present Clinical Development of C-1101 for Chronic Sciatica at 2026 BIO International Convention
BURLINGTON, MA — June 10, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that Andrew Hall, Chief Executive Officer will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California. READ MORE
Consano Bio Initiates Phase 1 Clinical Trial of C-1101, a Potential First-in-Class, Non-Opioid Therapy for Chronic Sciatica
BURLINGTON, MA — May 26, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today announced that the first patient has been successfully dosed in its first Phase 1 clinical trial (C-1101-101, NCT07264270 ) evaluating C-1101 in patients with chronic, painful lumbosacral radiculopathy (LSR), also known as chronic sciatica. READ MORE
Consano Bio Presents Preclinical Data on C-1101 at ORS 2026 Annual Meeting
BURLINGTON, MA — March 30, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced the presentation of preclinical data supporting its lead investigational therapy, C-1101, at the Orthopaedic Research Society (ORS) 2026 Annual Meeting in Charlotte, NC. The data were presented in a poster session highlighting translational research on immunomodulation and neuropathic pain. READ MORE
Consano Bio to Present at BIO Investment & Growth Summit 2026
BURLINGTON, MA — February 23, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida. READ MORE
Consano Bio Highlights Scientific Advisory Board Supporting Clinical Development of C-1101 for Chronic Sciatica
BURLINGTON, MA — February 13, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101 into clinical development for chronic lumbosacral radiculopathy (LSR), or chronic sciatica. READ MORE
Consano Bio Presents Favorable Nonclinical Safety Results for C-1101 at the American College of Toxicology 46th Annual Meeting
BURLINGTON, MA — November 21, 2025 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College of Toxicology (ACT) 46th Annual Meeting in Phoenix, AZ. READ MORE
CORPORATE PRESENTATION
